Michael P Dube
Overview
Explore the profile of Michael P Dube including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
2281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Park S, Faraci G, Nanda S, Ter-Saakyan S, Love T, Mack W, et al.
Microb Pathog
. 2021 Sep;
160():105209.
PMID: 34563611
People living with HIV have a high incidence of cardiovascular and neurological diseases as comorbid disorders that are commonly linked to inflammation. While microbial translocation can augment inflammation during HIV...
12.
Lake J, La K, Erlandson K, Adrian S, Yenokyan G, Scherzinger A, et al.
AIDS
. 2021 Mar;
35(9):1395-1402.
PMID: 33756511
Objectives: Fat quality and quantity may affect health similarly or differently. Fat quality can be assessed by measuring fat density on CT scan (greater density = smaller, higher quality adipocytes)....
13.
Garza J, Moser C, Kitch D, Currier J, Dube M, Stein J, et al.
AIDS Res Hum Retroviruses
. 2020 Jul;
36(10):831-834.
PMID: 32623904
People living with HIV (PLWH) who are on protease inhibitor (PI)-containing regimens have been shown to have increases in visceral adipose tissue (VAT) and a greater decrease in spine bone...
14.
Brown T, Moser C, Currier J, Ribaudo H, Rothenberg J, Kelesidis T, et al.
J Infect Dis
. 2020 Feb;
221(12):2083-2084.
PMID: 32022230
No abstract available.
15.
Hassan A, Wertheim J, Blumenthal J, Ellorin E, Dube M, Corado K, et al.
Medicine (Baltimore)
. 2019 Dec;
98(50):e18232.
PMID: 31852085
Transgender people continue to be at high-risk for HIV acquisition, but little is known about the characteristics of their sexual partners. To address this gap, we examined sociodemographic and sexual...
16.
Nanayakkara D, Sun X, Morris S, Louie S, Mulligan K, Overton T, et al.
AIDS Res Hum Retroviruses
. 2019 Mar;
35(7):608-614.
PMID: 30907095
Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) reduces bone mineral density in HIV-uninfected men who have sex with men (MSM). We hypothesized that PrEP with TDF-FTC would increase bone...
17.
Hoenigl M, Hassan A, Moore D, Anderson P, Corado K, Dube M, et al.
J Acquir Immune Defic Syndr
. 2019 Mar;
81(2):166-174.
PMID: 30865175
Background: Efficacy of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men is well documented in randomized trials. After trial completion, participants are challenged with acquiring PrEP on...
18.
Khan S, Funk C, Corado K, Morris S, Dube M
Open Forum Infect Dis
. 2018 Dec;
4(3):ofx149.
PMID: 30591921
No abstract available.
19.
Dube M, Chan E, Lake J, Williams B, Kinslow J, Landay A, et al.
Clin Infect Dis
. 2018 Dec;
69(7):1165-1172.
PMID: 30535188
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropic anti-inflammatory and immune regulatory effects in addition to glucoregulation. We evaluated inflammation and immune markers in suppressed human immunodeficiency virus (HIV) infection during...
20.
Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson P, et al.
Emerg Infect Dis
. 2018 Nov;
24(12).
PMID: 30457536
The effectiveness of oral HIV preexposure prophylaxis (PrEP) strongly depends on maintaining adherence. We investigated the association between substance use and PrEP adherence, as well as incident sexually transmitted infections...